These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37149443)

  • 21. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
    Clemens SAC; Folegatti PM; Emary KRW; Weckx LY; Ratcliff J; Bibi S; De Almeida Mendes AV; Milan EP; Pittella A; Schwarzbold AV; Sprinz E; Aley PK; Bonsall D; Fraser C; Fuskova M; Gilbert SC; Jenkin D; Kelly S; Kerridge S; Lambe T; Marchevsky NG; Mujadidi YF; Plested E; Ramasamy MN; Simmonds P; Golubchik T; Voysey M; Pollard AJ; ;
    Nat Commun; 2021 Oct; 12(1):5861. PubMed ID: 34615860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
    Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
    J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19.
    Wei J; Zhang W; Doherty M; Wallace ZS; Sparks JA; Lu N; Li X; Zeng C; Lei G; Zhang Y
    BMC Med; 2023 Feb; 21(1):78. PubMed ID: 36855108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models.
    van Doremalen N; Purushotham JN; Schulz JE; Holbrook MG; Bushmaker T; Carmody A; Port JR; Yinda CK; Okumura A; Saturday G; Amanat F; Krammer F; Hanley PW; Smith BJ; Lovaglio J; Anzick SL; Barbian K; Martens C; Gilbert SC; Lambe T; Munster VJ
    Sci Transl Med; 2021 Aug; 13(607):. PubMed ID: 34315826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
    Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
    J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India.
    Kaur U; Fatima Z; Maheshwari K; Sahni V; Dehade A; Kl A; Yadav AK; Kansal S; Jaisawal V; Chakrabarti SS
    Drug Saf; 2023 Jun; 46(6):553-563. PubMed ID: 37133805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
    Katikireddi SV; Cerqueira-Silva T; Vasileiou E; Robertson C; Amele S; Pan J; Taylor B; Boaventura V; Werneck GL; Flores-Ortiz R; Agrawal U; Docherty AB; McCowan C; McMenamin J; Moore E; Ritchie LD; Rudan I; Shah SA; Shi T; Simpson CR; Barreto ML; Oliveira VA; Barral-Netto M; Sheikh A
    Lancet; 2022 Jan; 399(10319):25-35. PubMed ID: 34942103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
    Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
    Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
    Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
    Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
    Kaplonek P; Cizmeci D; Kwatra G; Izu A; Lee JS; Bertera HL; Fischinger S; Mann C; Amanat F; Wang W; Koen AL; Fairlie L; Cutland CL; Ahmed K; Dheda K; Barnabas SL; Bhorat QE; Briner C; Krammer F; Saphire EO; Gilbert SC; Lambe T; Pollard AJ; Nunes M; Wuhrer M; Lauffenburger DA; Madhi SA; Alter G
    Nat Immunol; 2023 Jul; 24(7):1161-1172. PubMed ID: 37322179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T
    Swanson PA; Padilla M; Hoyland W; McGlinchey K; Fields PA; Bibi S; Faust SN; McDermott AB; Lambe T; Pollard AJ; Durham NM; Kelly EJ;
    Sci Transl Med; 2021 Nov; 13(620):eabj7211. PubMed ID: 34591596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expert review on global real-world vaccine effectiveness against SARS-CoV-2.
    Chuenkitmongkol S; Solante R; Burhan E; Chariyalertsak S; Chiu NC; Do-Van D; Husin M; Hwang KP; Kiertiburanakul S; Kulkarni PS; Lee PI; Lobo RC; Nghia CH; Ong-Lim A; Sivasampu S; Suah JL; Tok PSK; Thwaites G;
    Expert Rev Vaccines; 2022 Sep; 21(9):1255-1268. PubMed ID: 35748494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
    Torales J; Cuenca-Torres O; Barrios L; Armoa-Garcia L; Estigarribia G; Sanabria G; Lin MY; Antonio Estrada J; Estephan L; Cheng HY; Chen C; Janssen R; Lien CE
    Vaccine; 2023 Jan; 41(1):109-118. PubMed ID: 36404171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.
    Maaske J; Sproule S; Falsey AR; Sobieszczyk ME; Luetkemeyer AF; Paulsen GC; Riddler SA; Robb ML; Rolle CP; Sha BE; Tong T; Ahani B; Aksyuk AA; Bansal H; Egan T; Jepson B; Padilla M; Patel N; Shoemaker K; Stanley AM; Swanson PA; Wilkins D; Villafana T; Green JA; Kelly EJ
    Front Immunol; 2022; 13():1062067. PubMed ID: 36713413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine.
    Zamai L; Rocchi MBL
    Br J Pharmacol; 2022 Jan; 179(2):218-226. PubMed ID: 34331459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital.
    Limpawittayakul P; Sungkasubun P; Chaiwiriyawong W; Supavavej A; Weerasubpong B; Siripaibun J; Phanthunane C; Lamlertthon W; Ungtrakul T; Tawinprai K; Tantiyavarong W; Samdaengpan C
    Hum Vaccin Immunother; 2022 Nov; 18(6):2104058. PubMed ID: 35976687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study.
    Shoemaker K; Soboleva K; Branche A; Shankaran S; Theodore DA; Bari M; Ezeh V; Green J; Kelly E; Lan D; Olsson U; Saminathan S; Shankar NK; Villegas B; Villafana T; Falsey AR; Sobieszczyk ME
    Vaccines (Basel); 2024 Aug; 12(8):. PubMed ID: 39204009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.